Physiologically Speaking

MARCH 30, 2025

This talk dives into the science of cardiovascular fitness, its profound impact on longevity, and how to train smarter without overcomplicating it. I delivered it at the Golden Age Health Summit on March 15, 2025, in Austin, TX. Key Takeaways: Why VO2 max is your longevity superpower How aerobic fitness declines with age—and what to do about it A simplified 3-zone training model: Easy (50-70% HR max), Moderate (70-85% HR max), and Hard (85-100% HR max) Practical tips to train effectively w

Physiology 104

Physiology BMI Cholesterol Risk Factors 104

American College of Cardiology

MARCH 30, 2025

Implantation of an intra-aortic balloon pump (IABP) did not improve 60-day survival or bridge to heart replacement (HRT) therapies in patients with heart failure-cardiogenic shock (HF-CS) compared to standard care, according to a study presented during a Featured Clinical Research session at ACC.25 in Chicago and simultaneously published in JACC. The trial was stopped by the Data Safety and Monitoring Board at the prespecified interim analysis due to futility.

Cardiogenic Shock 75

Cardiogenic Shock Heart Failure Outcomes Aortic 75

Open Heart

MARCH 28, 2025

Background The significance of stress-test induced arrhythmias has been examined in prior studies, but there is no clear consensus regarding its significance. Objectives To determine the significance of stress test-induced arrhythmias. Methods Relevant studies examining arrhythmia in both exercise and pharmacological stress testing were searched for in PubMed, Embase and Cochrane databases from inception to 14 June 2023.

Arrhythmia 64

Arrhythmia Coronary Artery Disease Myocardial Infarction Atrial Fibrillation 64

Journal of Clinical Investigation - Cardiology

APRIL 1, 2025

Protein aggregates are emerging therapeutic targets in rare monogenic causes of cardiomyopathy and amyloid heart disease, but their role in more prevalent heart-failure syndromes remains mechanistically unexamined. We observed mislocalization of desmin and sarcomeric proteins to aggregates in human myocardium with ischemic cardiomyopathy and in mouse hearts with postmyocardial infarction ventricular remodeling, mimicking findings of autosomal-dominant cardiomyopathy induced by the R120G mutation

Myocardial Infarction 60

Myocardial Infarction Cardiomyopathy Heart Failure Heart Disease 60

Speaker: Simran Kaur, Co-founder & CEO at Tattva.Health

AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!

Patient Care

MIBHS

MARCH 31, 2025

When discussing heart health, heart attacks and cardiac arrest are two terms that are often mistaken for one another. While both are serious medical emergencies, they are not the same condition. Understanding the difference between heart attack and cardiac arrest can help in recognizing symptoms, seeking prompt medical care, and even saving lives. What is a Heart Attack?

Cardiac Arrest 52

Cardiac Arrest Heart Attack Heart attacks Chest Pain 52

Physiologically Speaking

MARCH 28, 2025

Greetings! Welcome to the Physiology Friday newsletter. Details about the sponsors of this newsletter including FSTFUEL electrolytes, Examine.com , and my book “VO2 Max Essentials ” can be found at the end of the post. You can find more products I’m affiliated with on my website. Physiologically Speaking is a reader-supported publication.

Exercise 71

Exercise Research Physiology Outcomes 71

CardiacWire

MARCH 26, 2025

New results from a vast Mayo Clinic meta-analysis suggest that combining ezetimibe with statins to lower LDL-C could have significant mortality and MACE benefits over statin monotherapy. Statins are one of the most prescribed drugs in the U.S., with over 25% of all adults 40 and up taking them. However, not everyone with high cholesterol benefits from statins, leading many drug developers to focus on novel ways to lower LDL-C levels.

Outcomes 59

Outcomes Cholesterol Article Research 59

Journal of Clinical Investigation - Cardiology

APRIL 1, 2025

Lysyl hydroxylase 2 (LH2) is highly expressed in multiple tumor types and accelerates disease progression by hydroxylating lysine residues on fibrillar collagen telopeptides to generate stable collagen cross links in tumor stroma. Here, we show that a galactosylhydroxylysyl glucosyltransferase (GGT) domain on LH2-modified type-VI collagen (Col6) to promote lung adenocarcinoma (LUAD) growth and metastasis.

Cancer 59

Cancer Pharmacology 59

DAIC

MARCH 28, 2025

tim.hodson Fri, 03/28/2025 - 15:23 Mar. 28, 2025 At theAmerican College of Cardiology (ACC) 2025 meeting,GE HealthCare will introduce RevolutionVibe, i a new computed tomography (CT) system with Unlimited One-Beat Cardiac imaging to deliver consistent, high-quality images for patients, even in challenging cases like atrial fibrillation and heavily calcified coronaries.

Technology 59

Technology Coronary Artery Disease Atrial Fibrillation Medicare 59

Heart BMJ

MARCH 26, 2025

Background Heart failure with preserved ejection fraction is a recognised outcome in patients with myocardial infarction, although heart failure with reduced ejection fraction is more common. Identifying early indicators specific to heart failure with preserved ejection fraction in patients with myocardial infarction could support targeted preventive strategies.

Aortic valve 52

Aortic valve Myocardial Infarction Preserved Ejection Fraction Heart Failure 52

American College of Cardiology

MARCH 29, 2025

After stent implantation, a three-month regimen of dual antiplatelet therapy (DAPT) was more effective than a one-month regimen at reducing adverse events without increasing bleeding risk in patients with a high bleeding risk (HBR), according to a Late-Breaking Clinical Trial presented at ACC.25 in Chicago. Furthermore, in patients with a low bleeding risk (LBR), a three-month regimen was found to be superior to 12 months for reducing bleeding risk and comparable in reducing adverse events.

Stents 68

Stents Stent Article 68

Frontiers in Cardiovascular Medicine

APRIL 1, 2025

Telocytes (TCs), a newly identified type of mesenchymal cell since 2010, possess substantial potential in maintaining tissue homeostasis, orchestrating organ development, and facilitating tissue regeneration. Their distribution in blood, the adventitia of blood vessels, and the intima implies a close association with vascular function. Ischemic heart disease (IHD), a significant challenge in cardiovascular disease, is characterized by the occlusion of major vessels, obstruction of collateral cir

Heart Disease 52

Heart Disease Cardiovascular Disease Circulation 52

Journal of Clinical Investigation - Cardiology

APRIL 1, 2025

Chimeric antigen receptor (CAR) T cell therapy shows promise for various diseases. Our studies in humanized mice and nonhuman primates demonstrate that hematopoietic stem cells (HSCs) modified with anti-HIV CAR achieve lifelong engraftment, providing functional antiviral CAR-T cells that reduce viral rebound after antiretroviral therapy (ART) withdrawal.

52

52

CardiacWire

MARCH 29, 2025

Intravascular lithotripsy (IVL) may have once been synonymous with Shockwave Medical, but its now rapidly becoming one of the hottest segments in interventional cardiology, spurred on by Abbotts new IVL Investigational Device Exemption (IDE) from the FDA. IVL is a minimally invasive medical catheter-based procedure that treats calcified plaque in blood vessels.

Plaque 59

Plaque Interventional Cardiology Stents Stent 59

Heart BMJ

MARCH 26, 2025

Background Pericardial complications following cardiac surgery are common and debilitating, significantly impacting patients’ survival. We performed this network meta-analysis to identify the most effective and safest preventions and treatments for pericardial complications following cardiac surgery. Methods We systematically searched PubMed/MEDLINE, EMBASE and Cochrane CENTRAL from inception to 22 January 2024.

Open-Heart Surgery 52

Open-Heart Surgery Pharmacology Atrial Fibrillation Pericarditis 52

American College of Cardiology

MARCH 30, 2025

Clopidogrel monotherapy was found to be more effective than aspirin monotherapy in lowering risk of major adverse cardiac and cerebrovascular events among patients at high risk of recurrent ischemic events who completed a standard duration of dual antiplatelet therapy (DAPT) following PCI, according to new research presented during a Late-Breaking Clinical Trial session at ACC.25 in Chicago and simultaneously published in The Lancet.

Research 56

Research Article 56

Frontiers in Cardiovascular Medicine

APRIL 1, 2025

IntroductionDepression is a significant comorbidity linked to poor subjective and objective health outcomes in cardiac patients. The paucity of data necessitates further research to elucidate the pathophysiological connection between depression and cardiac diseases in the presence of N-terminal pro-brain natriuretic peptide (NT-proBNP). Therefore, the current systematic review investigated the clinical significance of NT-proBNP as a predictive biomarker in cardiac patients with depressive sympto

Biomarkers 52

Biomarkers Coronary Artery Disease Article Myocardial Infarction 52

Journal of Clinical Investigation - Cardiology

APRIL 1, 2025

Sleep disturbance is bidirectionally associated with an increased risk of Alzheimers disease and other tauopathies. While the sleep-wake cycle regulates interstitial and cerebrospinal fluid (CSF) tau levels, the underlying mechanisms remain unknown. Understanding these mechanisms is crucial, given the evidence that tau pathology spreads through neuron-to-neuron transfer, involving the secretion and internalization of pathological tau forms.

52

52

ECG Guru

MARCH 30, 2025

This is an interesting case for your students who want to delve into dysrhythmias with an eye on detail. It is also a good teaching case for discussing treatment options when the diagnosis may be uncertain or controversial. I will start the discussion by admitting that I am not an expert of electrophysiology or complex dysrhythmias. My approach has always been more clinical - how is this rhythm affecting the patient and what are the chances it will deteriorate?

Dysrhythmia 64

Dysrhythmia RN Chest Pain Electrophysiology 64

Heart BMJ

MARCH 26, 2025

Heart failure (HF) is a complex syndrome which leads to significant morbidity and mortality, poor quality of life and extremely high costs to healthcare systems worldwide. Although progress in the management of HF in high-income countries is leading to an overall reduction in the incidence and mortality of HF, there is a starkly different scenario in low- and middle-income countries (LMICs).

Heart Failure 52

Heart Failure Quality of Life Heart Disease Risk Factors 52

American College of Cardiology

MARCH 30, 2025

One of the most significant modifications that middle-aged patients can take to prevent cardiovascular disease is lowering arterial hypertension, according to research presented during a Featured Clinical Research Session at ACC.25 in Chicago and simultaneously published in NEJM. At 50 years of age, absence of uncontrolled hypertension and four other cardiovascular risk factors was associated with a decade-longer lifespan compared with the presence of all five.

Risk Factors 57

Risk Factors Hypertension Cardiovascular Disease Research 57

Frontiers in Cardiovascular Medicine

MARCH 30, 2025

BackgroundPostoperative blood glucose levels significantly impact outcomes in cardiac surgery patients undergoing extracorporeal circulation (ECC) auxiliary to open heart surgery. While hypoglycemia and hyperglycemia are known risk factors for adverse outcomes, the optimal glycemic range for patients undergoing ECC remains unclear. This research examined the relationship between blood glucose levels and 90-day mortality in this high-risk group.MethodsThe data for this research were obtained from

Open-Heart Surgery 52

Open-Heart Surgery Circulation ICU Outcomes 52

Journal of Clinical Investigation - Cardiology

APRIL 1, 2025

Mitochondrial dysfunction fuels vascular inflammation and atherosclerosis. Mitochondrial calcium uptake 1 (MICU1) maintains mitochondrial Ca2+ homeostasis. However, the role of MICU1 in vascular inflammation and atherosclerosis remains unknown. Here, we report that endothelial MICU1 prevents vascular inflammation and atherosclerosis by maintaining mitochondrial homeostasis.

Atherosclerosis 52

Atherosclerosis Coronary Artery Bypass Graft Coronary Artery Disease Plaque 52

HCPLive

MARCH 27, 2025

Panelists discuss how selecting among the numerous approved biologic therapies for psoriasis requires a personalized approach that weighs factors such as efficacy data, safety profiles, comorbidities, insurance coverage, and administration preferences, with patient preferences playing a crucial role in the decision-making process, as involving patients in treatment selection enhances medication adherence and satisfaction and ultimately improves long-term outcomes.

Outcomes 52

Outcomes 52

ADN Center of Excellence

MARCH 31, 2025

In the continuously evolving world of healthcare, keeping up with the latest findings, technologies, and best practices is vital for medical professionals. One of the most effective ways to do this is through conferences that focus on medical education. These events are not just a way to earn continuing education credits; they are foundational to shaping how healthcare providers learn and apply knowledge in their practices.

Best Practices 52

Best Practices Education Technology 52

American College of Cardiology

MARCH 31, 2025

Sotatercept, a first-in-class novel activin-signaling inhibitor, led to a 76% lower risk of a composite of death from any cause, lung transplantation or hospitalization for worsening pulmonary arterial hypertension (PAH) compared to placebo in high-risk adults with PAH, according to results from the ZENITH study presented during a Clinical and Investigative Horizons session at ACC.25 in Chicago and simultaneously published in NEJM.

Transplant 63

Transplant Outcomes Pulmonary Hypertension 63

Frontiers in Cardiovascular Medicine

MARCH 30, 2025

BackgroundPediatric cardiomyopathies are rare but life-threatening conditions with high mortality. Limited data exists on their clinical features and risk factors, especially in Asian populations, highlighting the need for further research in this area.MethodsThis retrospective cohort study analyzed data from 212 pediatric patients diagnosed with hypertrophic cardiomyopathy (HCM), restrictive cardiomyopathy (RCM), or restrictive phenotype hypertrophic cardiomyopathy (RP-HCM) at a single center i

Risk Factors 52

Risk Factors Pediatrics Cardiomyopathy Pulmonary 52

Journal of Clinical Investigation - Cardiology

APRIL 1, 2025

Neuroretinal degenerations including retinitis pigmentosa (RP) comprise a heterogeneous collection of pathogenic mutations that ultimately result in blindness. Despite recent advances in precision medicine, therapies for rarer mutations are hindered by burdensome developmental costs. To this end, Von Hippel-Lindau (VHL) is an attractive therapeutic target to treat RP.

Ablation 52

Ablation 52

Open Heart

MARCH 28, 2025

Background High-sensitivity cardiac troponin tests have enhanced early myocardial infarction diagnosis, yet many patients still land in the observe zone (OZ). Guidelines suggest a 3-hour troponin measurement for those in the European Society of Cardiology (ESC) 0/1 hour-algorithm’s OZ, but evidence on extended troponin testing times and their impact on diagnostic accuracy and outcomes remains sparse.

Myocardial Infarction 52

Myocardial Infarction Outcomes 52

Nature Reviews - Cardiology

MARCH 27, 2025

Nature Reviews Cardiology, Published online: 28 March 2025; doi:10.1038/s41569-025-01147-w Countries globally face major challenges in the early diagnosis and treatment of hypercholesterolaemia and cardiovascular disease, with numerous health inequities by geography and income. Perseverance, hard work, integrity and commitment can transform aspiration into reality.

Cardiovascular Disease 55

Cardiovascular Disease 55

DAIC

MARCH 31, 2025

tim.hodson Mon, 03/31/2025 - 10:26 March 31, 2025 AGEPHA Pharma USA, LLC, has released clinical data that provides new information about how low-dose colchicine, 0.5 mg reduces the risk of major adverse cardiovascular events (MACE) and supports its use in the treatment of cardiovascular disease. The study, Effect of Colchicine on Progression of Known Coronary Atherosclerosis in Patients With Stable Coronary Artery Disease Compared To Placebo: The Ekstrom Trial, was presented at the American Col

Cardiovascular Disease 52

Cardiovascular Disease Plaque Coronary Artery Disease Heart attacks 52

Frontiers in Cardiovascular Medicine

MARCH 28, 2025

ST-elevation myocardial infarction (STEMI) is a critical cardiovascular emergency characterized by acute coronary artery occlusion and subsequent myocardial injury. The current standard of care is primary percutaneous coronary intervention (PPCI), which aims to rapidly restore epicardial blood flow. However, despite successful revascularization, microvascular obstruction (MVO) remains a major challenge, contributing to adverse clinical outcomes.

Thrombolysis 52

Thrombolysis STEMI Myocardial Infarction Article 52

Journal of Clinical Investigation - Cardiology

APRIL 1, 2025

Steatotic liver enhances liver metastasis of colorectal cancer (CRC), but this process is not fully understood. Steatotic liver induced by a high-fat diet increases cancer-associated fibroblast (CAF) infiltration and collagen and hyaluronic acid (HA) production. We investigated the role of HA synthase 2 (HAS2) in the fibrotic tumor microenvironment in steatotic liver using Has2HSC mice, in which Has2 is deleted from hepatic stellate cells.

Cancer 52

Cancer Diet 52

Open Heart

MARCH 28, 2025

Aims Mavacamten, the first approved myosin inhibitor for symptomatic obstructive hypertrophic cardiomyopathy (oHCM), addresses hypercontractility and left ventricular outflow tract (LVOT) obstruction. This study evaluates real-world experience with mavacamten, focusing on maintenance dose determination to optimise individual therapy and enhance patient safety.

Cardiomyopathy 52

Cardiomyopathy Biomarkers 52

Heart BMJ

MARCH 26, 2025

Advances in molecular genetics during the past decades led to seminal discoveries in the genetic basis of cardiovascular diseases, resulting in a new understanding of their pathogenesis, determinants of natural history and more recently paved the way for innovative therapies. A significant gap, however, exists between the rapidly increasing knowledge, especially of cardiovascular Mendelian disorders, and the medical applications in daily practice.

Innovation 52

Innovation Cardiovascular Disease 52

DAIC

MARCH 27, 2025

tim.hodson Thu, 03/27/2025 - 12:18 March 27, 2025 Abbott recently announced it has received CE Mark in Europe for the Volt PFA System to treat patients battling atrial fibrillation (AFib). With the earlier-than-expected CE Mark, Abbott has begun commercial PFA cases in the EU with physicians who have already gained experience with the Volt PFA System within Abbott's PFA clinical studies.

Ablation 52

Ablation AFIB Atrial Fibrillation Electrophysiology 52